Funding for this research was provided by:
DOD Peer Reviewed Cancer Research Program (W81XWH-16-1-0329)
National Cancer Institute of the National Institutes of Health (R01 CA220581-01A1, R01CA208236-01A1, 1U24CA199374-01, 1U01 CA239055-01, R01CA216579-01A1, R01CA202752-01A1)
United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service VA Merit Review Award (IBX004121A)
DOD Prostate Cancer Idea Development Award (W81XWH-15-1-0558)
DOD Lung Cancer Investigator-Initiated Translational Research Award (W81XWH-18-1-0440)
Text and Data Mining valid from 2019-10-17
Received: 19 December 2018
Accepted: 13 September 2019
First Online: 17 October 2019
Ethics approval and consent to participate
: The study was considered HIPAA compliant and was approved by the Institutional Review Board at the UH Cleveland Medical Center, and the need for informed consent was waived.
: Not applicable.
: Dr. Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. He is also a scientific advisory consultant for Inspirata Inc. In addition, he currently serves as a scientific advisory board member for Inspirata Inc. Dr. Thorat has received research funding from Genomic Health and Ventana Medical Systems, Inc. Tucson, AZ. Dr. Badve is funded by NIH/NCI R01 CA194600 and by research funds from Dako/Agilent. He is on the speaker bureau for Roche/Genentech and Genomic Health. He has also participated in advisory board meetings for Genentech/Roche, Genomic Health Inc., Clearlight, Athenax, and Konica-Minolta. He is also a co-founder of two startups seeking to establish novel genomic assays for breast (SYSGenomics) and colon cancer (YeSSGenomics).